CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
HypoCyclo aims to develop new therapies for Triple Negative Breast Cancer by combining chemotherapy with photodynamic therapy using innovative cyclodextrin-based nanoparticles. These nanoparticles will encapsulate the drug paclitaxel and release oxygen to enhance treatment effectiveness.
Among all breast cancers (BC) affecting female population worldwide, 20% is represented by Triple Negative Breast Cancer (TNBC), an aggressive subtype with very limited therapeutic options and poor survival.
Seeking for innovative TNBC therapies, HypoCyclo aims at the optimal combination of chemotherapy and photodynamic therapy (PDT).
We envisage novel, tailored cyclodextrin (CyD)-based polymeric nanoparticles (NPs) able to load “known” therapeutic agents and decorated with a photosensitizer as…
CONSIGLIO NAZIONALE DELLE RICERCHE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
